BioSpace News Archive

Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2024 fiscal year will be released on Tuesday, November 14, 2023.

Variantyx announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of chromosomal abnormalities that correlate with clinical symptoms manifested in a fetus or a pregnancy, that may result in a genetic disorder or pregnancy loss.

DENTSPLY SIRONA Inc. announced its participation at upcoming conferences.

TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 40,700 shares of its common stock to thirty-one newly-hired employees, with a grant date of November 6, 2023.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place November 14-16, 2023.

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension, the first FDA approved renal denervation therapy in the United States.

Crinetics Pharmaceuticals, Inc. announced that on November 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 83,600 shares of its common stock to four new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Mirum Pharmaceuticals, Inc. announced that on November 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 20,000 shares of common stock and 10,000 restricted stock units to five new employees under Mirum’s 2020 Inducement Plan.

GC Genome Corporation, a leading diagnostics company, announced that it has entered into a collaboration and exclusive license agreement with MP Group CO., LTD, Bangkok, Thailand to commercialize ‘Genome Health’ for genetic health checkups.

Mirati Therapeutics, Inc. today announced that following a re-examination procedure, the Company has received a positive opinion from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on KRAZATI ®.